Nasal cavity and paranasal sinus squamous cell carcinoma
MONDO:0044787A rare, keratinizing or non-keratinizing squamous cell carcinoma arising from the mucosal epithelium of the nasal cavity or the paranasal sinuses. It affects most often the maxillary sinus. Less frequently, it arises from the nasal cavity, ethmoid sinus, sphenoid sinus, and frontal sinus. Symptoms include nasal fullness, epistaxis, rhinorhea, pain, and paresthesia. Patients with nasal squamous cell carcinoma usually present earlier than patients with maxillary sinus carcinoma and have a better prognosis compared to the latter group.
Also known as: nasal cavity and paranasal sinus squamous cell cancer, nasal cavity and paranasal sinus squamous cell carcinoma
2861 clinical trials for this condition and its sub-types, 9 tagged with Nasal cavity and paranasal sinus squamous cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Nasal cavity and paranasal sinus squamous cell carcinoma
-
Chemo before surgery may save eye and skull in sinus cancer patients
Disease control OngoingThis study tests whether giving chemotherapy before surgery and radiation can help preserve the eye and skull base in people with advanced nasal and sinus cancer. About 82 participants will either get chemo first or go straight to surgery and radiation. The goal is to see if the …
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental triple therapy takes on head and neck cancer
Disease control OngoingThis early-phase trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation in people with advanced head and neck cancer that has spread to nearby tissues. The main goals are to find the safest dose and to see what side effects occ…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC